EULAR 2019: UCB's bimekizumab continues to impress

14 June 2019

Bimekizumab is a crucial pipeline drug for UCB (Euronext: UCB) – allowing the company’s to look beyond Cimzia (certolizumab pegol) in immunology – so each successful data read-out is a relief for the Belgian drugmaker.

The latest positive milestone has been announced at EULAR, with new Phase IIb data showing that it delivered improvements in disease activity and in important patient-reported outcomes, such as pain, fatigue, morning stiffness, function and quality of life, for patients with ankylosing spondylitis (AS).

These improvements, which occurred at different doses, are hypothesized to be associated with bimekizumab’s mechanism of action, which potently and selectively neutralizes both interleukin (IL)-17A and IL-17F cytokines.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK